European Immunogenicity Platform 11th Open Scientific Symposium on immunogenicity of biopharmaceuticals.

antidrug antibody gene therapy immunogenicity risk assessment

Journal

Bioanalysis
ISSN: 1757-6199
Titre abrégé: Bioanalysis
Pays: England
ID NLM: 101512484

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 18 8 2020
medline: 13 5 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Given the expanding number of complex therapeutic protein drugs and advanced therapy medicinal products that are being developed, improving our ability to assess the potential immunogenicity of biologics is critical to ensuring treatment efficacy and patient safety. In this context, the European Immunogenicity Platform annual meeting provides opportunities for experts from industry and academia, regulators and clinicians to convene and discuss immunogenicity assessment methods and tools. This report summarizes the key messages on immunogenicity testing, prediction, clinical relevance and advanced therapy medicinal products discussed at the 11th Open Scientific European Immunogenicity Platform Symposium on Immunogenicity of Biopharmaceuticals, Lisbon, Portugal, 17-19 February 2020.

Identifiants

pubmed: 32803994
doi: 10.4155/bio-2020-0150
doi:

Types de publication

Clinical Conference Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1043-1048

Auteurs

Sophie Tourdot (S)

BioMedicine Design, Pfizer Inc., Andover, MA 01810, USA.

Carolina B Quaglia (CB)

Immunoinformatics & Machine Learning, Technical University of Denmark, Kgs, Lyngby 2800, Denmark.

Paul Chamberlain (P)

NDA Advisory Board, NDA Regulatory Science Ltd., Leatherhead KT229DF, United Kingdom.

Anne S De Groot (AS)

EpiVax, Providence, RI, USA & University of Georgia, Athens, GA 02909, USA.

Nikki Dellas (N)

Codexis, Redwood City, CA 94063, USA.

Eric Guillemare (E)

Translational Medicine & Early Development - Sanofi Montpellier, Montpellier 34184, France.

Arno Kromminga (A)

Bioagilytix, Hamburg 22339, Germany.

Gregor P Lotz (GP)

Roche Pharma Research & Early Development, Large Molecule Bioanalytical Sciences, Roche Innovation Center, Penzberg 82377, Germany.

Federico Mingozzi (F)

Spark Therapeutics, Philadelphia, PA 19104, USA.

Luca Piccoli (L)

Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona 6500, Switzerland.

Samuel Pine (S)

Bioanalysis & Immunogenicity, Ablynx NV, a Sanofi Company, Zwijnaarde 8052, Belgium.

Susan Richards (S)

Sanofi-Genzyme, TMED, Framingham, MA 01701, USA.

Günter Waxenecker (G)

Austrian Medicines & Medical Devices Agency, Department of Biologicals, Preclinical & Statistical Assessment, Vienna 1200, Austria.

Daniel Kramer (D)

Sanofi R&D, Translational Medicine & Early Development, Frankfurt am Main 65926, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH